XYLOCAINE (lidocaine) by AstraZeneca is clinical pharmacology mechanism of action: lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Approved for facial volume deficit, nasolabial folds, facial wrinkles and folds. First approved in 1965.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
XYLOCAINE (lidocaine) is a local anesthetic that stabilizes neuronal membranes by inhibiting ionic fluxes required for nerve impulse conduction, providing rapid topical anesthesia within 3-5 minutes. It is indicated for facial volume deficit, nasolabial folds, and facial wrinkles and folds. The drug is formulated as an oral aerosol and has been approved since 1965.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and focus shift to generic optimization or adjacent formulations.
CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset of anesthesia: Lidocaine Ointment 5% effects local, topical anesthesia. The…
Worked on XYLOCAINE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Lidocaine for LESS Postoperative Shoulder Pain Alleviation
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
Efficacy and Safety of Stellate Ganglion Block With Lidocaine Combined Platelet-rich Plasma to Treat Chronic Migraine
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on XYLOCAINE in its LOE phase offers career exposure to generic competition management, payer negotiation, and portfolio optimization strategies. Roles are likely focused on maximizing remaining market value and supporting transition to post-patent exclusivity models rather than innovation-driven growth.